Fiche centre
University of Iowa
Iowa City — United States
Essais liés34clinical trials
VilleIowa Citylocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07464028
Essais cliniques associés
34| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| INBRX-106 - Hexavalent OX40 agonist antibody | Cancer | Phase 1/2 | NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | RECRUITING |
| [O-15]-Water PET Myocardial Perfusion Imaging (MPI) | Maladie coronarienne | Phase 3 | NCT05134012 | RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW) | COMPLETED |
| Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System | Insuffisance cardiaque | Non applicable | NCT05064709 | AIM HIGHer — Assessment of CCM in HF With Higher Ejection Fraction | RECRUITING |
| CLN-978 | Lupus | Phase 1 | NCT06613360 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus | RECRUITING |
| Flow diversion | Accident vasculaire cérébral | Non applicable | NCT07143019 | PIANO — The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms | RECRUITING |
| WiSE System | Insuffisance cardiaque | Non applicable | NCT02922036 | SOLVE-CRT — Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients | ACTIVE_NOT_RECRUITING |
| DYNE-101 | Myopathies | Phase 1/2 | NCT05481879 | ACHIEVE — Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 | ACTIVE_NOT_RECRUITING |
| Terazosin 5 MG | Parkinson | Phase 2 | NCT07464028 | TAME-PD: — Terazosin And Metabolic Energetics in Parkinson's Disease | SUSPENDED |
| rondecabtagene autoleucel | SEP | Phase 3 | NCT07188558 | PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | RECRUITING |
| Nicotine Transdermal Patch | Alzheimer | Phase 2 | NCT02720445 | Memory Improvement Through Nicotine Dosing (MIND) Study | COMPLETED |
| ZL-1310 | Cancer | Phase 3 | NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | RECRUITING |
| Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson | À vérifier | NCT04994015 | Parkinson's Foundation PD GENEration Genetic Registry | RECRUITING |
| BBP-418 (ribitol) | Myopathies | Phase 3 | NCT05775848 | Fortify — Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) | ACTIVE_NOT_RECRUITING |
| Low Dose Benfotiamine | Alzheimer | Phase 2 | NCT06223360 | A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | ACTIVE_NOT_RECRUITING |
| rapcabtagene autoleucel | Lupus | Phase 2 | NCT06581198 | A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) | ACTIVE_NOT_RECRUITING |
| Obinutuzumab | Cancer | Phase 3 | NCT06084936 | GLOBRYTE — A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | RECRUITING |
| Terazosin (Hytrin) | Alzheimer | Phase 2 | NCT07796308 | TAME-AD — Terazosin And Metabolic Engagement in Alzheimer's Disease | NOT_YET_RECRUITING |
| Phenotype, Genotype & Biomarkers in ALS and Related Disorders | Sclérose latérale amyotrophique | À vérifier | NCT02327845 | Phenotype, Genotype & Biomarkers in ALS and Related Disorders | ACTIVE_NOT_RECRUITING |
| GRASP-01-002 — Defining Endpoints in Becker Muscular Dystrophy | Myopathies | À vérifier | NCT05257473 | GRASP-01-002 — Defining Endpoints in Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
| Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | Myopathies | À vérifier | NCT03981575 | Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | RECRUITING |
| Solanezumab | Alzheimer | Phase 3 | NCT02008357 | A4 — Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss | COMPLETED |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| RGX-202 | Myopathies | Phase 2/3 | NCT05693142 | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING |
| CDLink — CureDuchenne Link®: A Resource for Research | Myopathies | À vérifier | NCT04972604 | CDLink — CureDuchenne Link®: A Resource for Research | COMPLETED |
| AOC-1020 | Myopathies | Phase 3 | NCT07038200 | FORTITUDE-3 — A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | RECRUITING |
| Sevasemten 10 mg | Myopathies | Phase 2 | NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | COMPLETED |
| Sevasemten | Myopathies | Phase 2 | NCT06066580 | MESA — Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | ENROLLING_BY_INVITATION |
| ALLO-329 | Lupus | Phase 1 | NCT07085104 | RESOLUTION — A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease | RECRUITING |
| P-CD19CD20-ALLO1 Cells | Lupus | Phase 1 | NCT06984341 | A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) | WITHDRAWN |
| CTX112 | Myopathies | Phase 1 | NCT06925542 | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease | RECRUITING |
| Focal cortical cooling | Épilepsie | Non applicable | NCT06391294 | Neuronal and Network Mechanisms of Electrocortical Stimulation | ENROLLING_BY_INVITATION |
| Agricultural Health Study Follow-up | Parkinson | À vérifier | NCT01399411 | Agricultural Health Study Follow-up | COMPLETED |
| AB-1003 dose level 1 | Myopathies | Phase 1/2 | NCT05230459 | A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1) | ACTIVE_NOT_RECRUITING |
| Anti-hypertensive therapy | Hypertension | Phase 4 | NCT02299414 | Chronic Hypertension and Pregnancy (CHAP) Project | COMPLETED |